OncoMatch/Clinical Trials/NCT06211114
Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma
Is NCT06211114 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including PD-(L)1 inhibitor and Axitinib for collecting duct carcinoma.
Treatment: PD-(L)1 inhibitor · Axitinib — This is a phase II trial to evaluate the efficacy and safety of immune checkpoint inhibitors in combination with axitinib for previously treated advanced collecting duct carcinoma.
Check if I qualifyExtracted eligibility criteria
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy — after metastasis
Have received prior systemic therapy after previous metastasis for collecting duct carcinoma
Cannot have received: anti-PD-1 therapy
Prior Anti-PD-1
Cannot have received: anti-PD-L1 therapy
Prior PD-L1
Cannot have received: VEGFR inhibitor (axitinib)
Prior axitinib
Lab requirements
Blood counts
ANC ≥ 1.5×10^9/L. Platelets ≥ 100×10^9/L. Hemoglobin ≥ 9.0g/dL or ≥ 5.6mmol/L.
Kidney function
Serum creatinine ≤ 1.5×ULN
Liver function
Serum total bilirubin ≤1.5×ULN or total bilirubin levels >1.5×ULN with direct bilirubin ≤ ULN. AST and ALT ≤2.5 × ULN, ≤5×ULN in those with hepatic metastasis.
Cardiac function
Left ventricular ejection fraction (LVEF) ≥ 50%
Adequate function of vital organs: Bone marrow function (without blood or blood products transfusion, without hematopoietic stimulating factor or other medication to improve blood cell count within 2 days prior to first dose of study drug): Absolute neutrophil count (ANC) ≥ 1.5×109/L. Platelets ≥ 100×109/L. Hemoglobin ≥ 9.0g/dL or ≥ 5.6mmol/L. Renal function: Serum creatinine ≤ 1.5×ULN. Hepatic function:Serum total bilirubin ≤1.5×ULN or total bilirubin levels >1.5×ULN with direct bilirubin ≤ ULN. AST and ALT ≤2.5 × ULN, ≤5×ULN in those with hepatic metastasis. Endocrine function: Normal thyroid stimulating hormone, or abnormal TSH whilst normal FT3 and FT4. Coagulation function: INR or PT ≤1.5×ULN, and aPTT ≤1.5×ULN. Subjects receiving anticoagulant therapy (e.g., heparin or warfarin) may participate in the study with PT or APTT levels within the scope of the proposed therapy and monitored during study treatment. Left ventricular ejection fraction (LVEF) ≥ 50%.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify